Wie hoch ist der Preis für Psyence Biomedical Ltd. (PBM)

Preis für Psyence Biomedical Ltd. (PBM) ist $3.20

Wie hoch ist die Marktkapitalisierung für Psyence Biomedical Ltd. (PBM)

Marktkapitalisierung für Psyence Biomedical Ltd. (PBM) ist $60.86K

Psyence Biomedical Ltd. (PBM) Preis und Marktkapitalisierung

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

Preis für PBM	Vermögenswert B	Marktkapitalisierung von B	Ergebnisse
$283,051,657 $60.86K	NVDA	$5.383T	+8,845,364,173.88%
$232,577,486 $60.86K	AAPL	$4.423T	+7,268,046,333.40%
$218,748,062 $60.86K	GOOG	$4.160T	+6,835,876,850.49%
$192,613,746 $60.86K	MSFT	$3.663T	+6,019,179,465.50%
$152,017,919 $60.86K	AMZN	$2.891T	+4,750,559,858.79%

Preis für PBM

Vermögenswert B

Marktkapitalisierung von B

Ergebnisse

$283,051,657 $60.86K